MedTrace Logo

PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer

NCT01281787 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2014-06-18

No results posted yet for this study

Summary

The aim of this study is to assess whether prophylactic treatment with metoprolol or losartan is able to reduce the incidence of atrial fibrillation (AF) in patients undergoing thoracic surgery for lung cancer, showing elevated plasma levels in NT probrain natriuretic peptide (NT-proBNP), measured in the perioperative period.

Conditions

Interventions

DRUG

Metoprolol

Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay

DRUG

Losartan

Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Daniela Cardinale, MD · European Institute of Oncology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2013-06-30
Completion
2013-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281787 on ClinicalTrials.gov